title: Repligen
id: 42211934
Repligen Corporation is an American company devoted to the development and production of materials used in the manufacture of biological drugs The company is based in Waltham Massachusetts and was incorporated in Delaware in A public company Repligen is listed on the NASDAQ exchange under the symbol RGEN In February Repligen had employed people about of these based in Sweden br br br Business model br Before Repligen maintained dual capabilities in developing pharmaceutical therapeutics drug discovery and development and the development of materials supporting biological drug manufacture bioprocessing business A decision was made in to focus on the bioprocessing business and reduce research and development expenditures In the period of to the majority of sales by the company were concentrated in the single Protein A product line br br br Sales and revenue br Repligen employs a direct sales model to users of its products in the United States with some sales through intermediaries in certain foreign markets More than of sales have been to customers in the United States and Sweden during the period Long term supply agreements have been established with major customers of the Protein A products agreements which expire between and barring re negotiation br As a result of royalty generating out licensing royalty revenue from Bristol Myers Squibb has been in the to range as a proportion of total revenue during the period in comparison to revenue from sales the largest customer accounted for to of revenue during the same period br As a consequence of current operations about one third each of revenue and cost and expenses are denominated in Swedish krona currency the remaining two thirds denominated in United States dollars this presents a risk to the business based on unpredictable fluctuations in currency exchange rates br br br Intellectual property br The company s Protein A related offerings are supported by proprietary technology trade secrets and patent filings One patent was granted in April and has been extended so that it remains in effect until Patents are pending on elements of the OPUS chromatography product line and enabling technology has been licensed from BioFlash Partners Repligen retains an exclusive license to intellectual property owned by the University of Michigan in relation to the Orencia product divested to Bristol Myers Squibb br br br Facilities br Repligen s company headquarters are housed together with its manufacturing facility in Waltham Massachusetts br Repligen maintains manufacturing facilities in Waltham Massachusetts and Lund Sweden Growth factor products and the native form of Protein A are manufactured in Sweden recombinant forms of Protein A are manufactured in both the United States and Sweden assembly of the OPUS chromatography product line is done in the United States br The lease on the main Waltham facility extends through A second smaller Waltham facility was leased through the end of and is now rented on a monthly basis In Lund four buildings are under lease three expiring in mid and the fourth extending to late br br br Corporate history and governance br Alexander Rich was a co founder of Repligen and served as Chairman Emeritus of Repligen s board of directors Rich had been a member of the Board since Paul Schimmel is also a co founder of Repligen and he is the Ernest and Jean Hahn Professor at The Skaggs Institute for Chemical Biology at The Scripps Research Institute He used to be the John D and Catherine T MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at MIT br As of the company s President and Chief Executive Officer is Tony J Hunt br br br Acquisitions and in licensing br In early Repligen licensed technology from BioFlash which it subsequently incorporated into the OPUS line of pre packed chromatography columns br In Repligen acquired bioproduction assets from Novozymes for million which doubled the company s bioprocessing capabilities br In December the company acquired TangenX for million br In September Repligen acquired a fluid management company Metenova br br br Divestments and out licensing br In an agreement was struck to divest certain intellectual property rights to Bristol Myers Squibb around the drug Orencia in exchange for ongoing royalty payments through the end of br At the end of Repligen out licensed its spinal muscular atrophy program in particular the small molecule candidate drug RG to Pfizer This divestment included licensing rights to two patents to Pfizer br At the start of the company out licensed its Friedreich s ataxia program including a library of histone deacetylase inhibitor compounds to BioMarin Pharmaceutical for US and future milestone and royalty payments br br br Terminations and moth balling br Development of an imaging agent designated RG based on a synthetic human hormone was halted in following a request by the USFDA for additional safety and efficacy data beyond that provided in a New Drug Application NDA submission a Marketing Authorization Application had been submitted in parallel to the EMA br br br Products and services br Repligen is a major supplier of Protein A both native and recombinant forms to the pharmaceutical industry In Protein A accounted for the majority of the company s product sales The company also provides growth factors to increase the productivity of cell based bioproduction multiple alternating tangential flow ATF systems and a line OPUS of chromatography columns scaled to manufacture of product for testing in clinical trials br The OPUS product line contains a range of column sizes the size and composition of which are dependent upon customer requirements thus the full name of Open Platform User Specified The smaller sizes of columns depend upon proprietary technology licensed from BioFlash Partners while the larger sizes are based on Repligen developed proprietary technology br br br Notes br br br br Forbes Alexander Rich Profiles Forbes Archived from the original on March Retrieved March br Gen Eng Biotechnol News February BioMarin Nabs Repligen s HDACi Compound Library News Discovery Development Gen Eng Biotechnol News paper Vol no p br International New York Times Repligen Corporation Business Day International New York Times Company Information Archived from the original on March Retrieved March br Motley Fool Repligen Corp Key Executives RGEN The Motley Fool Archived from the original on March Retrieved March br Repligen Corporation Form K SEC Documents Form K Repligen Commission File Number retrieved March br Street Insider September Repligen RGEN Replaces Board Member Alex Rich with Alfred Goldberg Street Insider Archived from the original on March Retrieved March br br br External links br Official website br br Business data for Repligen Corporation 